Sitagliptin vs Teneligliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Sitagliptin · Januvia
Marketed by Merck & Co. and partners
NCT00087516 · Phase 3 · completed
The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.
Next expected readout: September 2029 · NCT07108985 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)
Result source: NCT00086502
Teneligliptin · Tenelia
Marketed by Tanabe Pharma Corporation and partners
NCT00974090 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 trial added teneligliptin 20 mg or placebo to glimepiride in 194 Japanese adults with type 2 diabetes. The primary endpoint was the change in HbA1c at week 12. Teneligliptin lowered HbA1c by 1.0 percentage point more than placebo (p<0.001), so the primary endpoint was met. A 40-week open-label teneligliptin period followed. Source: the peer-reviewed trial report (Kadowaki and Kondo 2014) and CT.gov posted results.
Reported efficacy
HbA1c (Change from Visit 1(Baseline Visit) in HbA1c at Visit 5(week 16)): Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL). (met)
Result source: NCT01805830
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Sitagliptin | Teneligliptin |
|---|---|---|
| HbA1c, change | -0.6% vs 0.2%−0.8 vs placeboNCT000875167 other results
| -0.7% vs -0.0%−0.7 vs placeboNCT0292406412 other results
|
| Body weight, change (kg) | -0.5 vs -1.4vs Oral SemaglutideNCT040178321 other result
| —Not posted · NCT01798238 |
| HbA1c below 7% | 49.5% vs 36.8%+12.7 vs placeboNCT014856144 other results
| —Not posted · NCT01798238 |
| Fasting plasma glucose, change | -0.7 vs 0.3−0.9 vs placeboNCT000875167 other results
| -0.8 vs 0.2−0.9 vs placeboNCT0292406413 other results
|
| 3-point MACE (% with event) | —Not posted · NCT01529541 | —Not posted · NCT01798238 |
HbA1c, change
- Sitagliptin
- -0.6% vs 0.2%−0.8 vs placeboNCT00087516
7 other results
- -0.8% vs -0.1% NCT00086502
- -0.8% vs 0.2% NCT00087516
- -0.0% vs 0.2% NCT01485614
- -1.1% vs -0.7% NCT02791490
- -0.1% vs -1.0% NCT01485614
- -0.2% vs -0.7% NCT01485614
- -0.5% vs -1.1% NCT01907854
- Teneligliptin
- -0.7% vs -0.0%−0.7 vs placeboNCT02924064
12 other results
- -0.9% vs -0.1% NCT02916706
- -0.6% vs 0.2% NCT00998881
- -0.9% vs 0% NCT02354222
- -0.7% vs 0.3% NCT00974090
- -0.8% vs 0.1% NCT00628212
- -0.8% vs 0.1% NCT00628212
- -0.9% vs -0.3% NCT00971243
- -0.9% vs 0.1% NCT00628212
- -0.8% vs -0.3% NCT00971243
- -0.7% vs -0.3% NCT00971243
- -0.6% vs -0.3% NCT00971243
- -0.9% vs -0.1% NCT02081599
Body weight, change (kg)
- Sitagliptin
- -0.5 vs -1.4vs Oral SemaglutideNCT04017832
1 other result
- -1.8 vs -3.3 NCT01907854
- Teneligliptin
- —Not posted · NCT01798238
HbA1c below 7%
- Sitagliptin
- 49.5% vs 36.8%+12.7 vs placeboNCT01485614
4 other results
- 28.8% vs 16.6% NCT02791490
- 15.6% vs 5.7% NCT02791490
- 28.4% vs 33.3% NCT01485614
- 49.5% vs 77.8% NCT01485614
- Teneligliptin
- —Not posted · NCT01798238
Fasting plasma glucose, change
- Sitagliptin
- -0.7 vs 0.3−0.9 vs placeboNCT00087516
7 other results
- -0.9 vs 0.1 NCT00086502
- -0.9 vs 0.3 NCT00087516
- 0.4 vs 0.3 NCT01485614
- -1.6 vs -0.9 NCT02791490
- -0.5 vs -1.0 NCT04017832
- 0.6 vs -1.1 NCT01485614
- -0.2 vs -1.7 NCT01485614
- Teneligliptin
- -0.8 vs 0.2−0.9 vs placeboNCT02924064
13 other results
- -1.2 vs -0.1 NCT02916706
- -1.1 vs -0.0 NCT00998881
- -1.1 vs -0.4 NCT01072331
- -1.1 vs -0.4 NCT01072331
- -0.3 vs 0.6 NCT02354222
- -0.8 vs 0.2 NCT00628212
- -0.8 vs 0.2 NCT00628212
- -1.2 vs -0.2 NCT00971243
- -0.9 vs 0.2 NCT00628212
- -1.0 vs -0.2 NCT00971243
- -0.8 vs -0.2 NCT00971243
- -0.9 vs -0.2 NCT00971243
- -0.3 vs 0.4 NCT02081599
3-point MACE (% with event)
- Sitagliptin
- —Not posted · NCT01529541
- Teneligliptin
- —Not posted · NCT01798238
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Sitagliptin: 9 of 9 rows · Teneligliptin: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Sitagliptin Rows use multiple source trials | Teneligliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -0.23 mmol/L @ 104wk*100 mga,b,c NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.1 mg/dL as posted show 3 more doses-0.1 mmol/L @ 104wk*100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -1.8 mg/dL as posted -0.23 mmol/L @ 104wk*200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.1 mg/dL as posted -0.32 mmol/L @ 104wk*200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -5.7 mg/dL as posted | -0.69 mmol/L @ 52wk*a,b,c NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.4 mg/dL as posted show 1 more dose-0.94 mmol/L @ 52wk* NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17 mg/dL as posted |
| Glucose Change mg/dL absolute change · mmol/L | -1.06 vs -1.93 Glibenclamide mmol/L @ 1.857wk*50 mgd,e,f,g NCT02318693 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -19.1 mg/dL as posted | -1.72 vs -0.3 placebo mmol/L @ 4wk*20 mga,d,e,f,g NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -30.921 mg/dL as posted show 1 more dose-1.93 vs -0.3 placebo mmol/L @ 4wk*10 mg NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -34.722 mg/dL as posted |
| HbA1c absolute change · percentage points No placebo or comparator arm | -1.27% (n=183) @ 24wka,d,e,f NCT01519674 · Phase 4 · registry result, not featured evidence · combination show 2 more doses-1.51% (n=189) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination -1.15% (n=187) @ 24wk NCT01519674 · Phase 4 · registry result, not featured evidence · combination | -0.94% @ 24wkteneligliptin 20mgd,e,f NCT01798238 · Phase 3 · sponsor-reported, not registry data |
| PPG 2h Change mg/dL absolute change · mmol/L | -6.01 vs -2.47 Sitagliptin mmol/L @ 8wk*d,e,f,h NCT00729326 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -108.35 mg/dL as posted | -1.96 vs 0.13 placebo mmol/L @ 24wk*d,e,f,h NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.3 mg/dL as posted |
| Weight percent change · % of baseline | -1% (n=335) vs -2% (n=322) Oral Semaglutide @ 26wk100 mge,f,i NCT04017832 · Phase 3 · registry result, not featured evidence | 0.09% (n=77) vs -1.34% (n=76) placebo @ 24wke,f,i NCT02354222 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 74.6%100 mgj NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results67.6%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 69.1%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 67.6%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 9% NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0.7%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 10.8%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.7%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 6.2%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 12.9%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 3% NCT01131182 · Phase 4 · registry result, not featured evidence 20.5%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 10.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence 2.5%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1% NCT01485614 · Phase 3 · registry result, not featured evidence 4.8%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 10.6%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.6% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence | 1%Teneli / Teneli + SUk NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results—Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15.7%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 19.5%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 11.8%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 5.2% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 7.1%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 9.3%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 7.4%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 10%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 2%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 15.9%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20.9%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 11.8%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 21.8%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.8%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 1.2%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 6.2%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.3%100 mgj NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results4.2%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02556918 · Phase 4 · registry result, not featured evidence —100 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence —Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence —Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination — NCT02256189 · Phase 4 · registry result, not featured evidence — NCT01859793 · Phase 4 · registry result, not featured evidence — NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT02318693 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 1.5%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 1.5%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination —Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence —Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination —Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination — NCT01131182 · Phase 4 · registry result, not featured evidence 7.9%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 3.9%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination — NCT00686634 · Phase 4 · registry result, not featured evidence — NCT00729326 · Phase 4 · registry result, not featured evidence —100 mg NCT04017832 · Phase 3 · registry result, not featured evidence — NCT01485614 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence —Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 0.5% NCT03115112 · Phase 3 · registry result, not featured evidence — NCT02791490 · Phase 3 · registry result, not featured evidence | 1%Teneli / Teneli + SUk NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results—Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 1.6%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 0% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 3.3%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 6.7%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 5.3%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 6.3%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination —20 mg NCT01072331 · Phase 3 · registry result, not featured evidence —10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 2%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.3%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.2%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.2%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.3%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 1.3%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 2.5%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 7.7%100 mgj NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results10.1%100 mg/100 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 10%200 mg/200 mg NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%100 mg NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 80% NCT02556918 · Phase 4 · registry result, not featured evidence 0%100 mg NCT03267576 · Phase 4 · registry result, not featured evidence 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence 0%Sitagliptin (Diabetics and Control NCT02639637 · Phase 4 · registry result, not featured evidence 0%Sitagliptin and Valsartan (Control NCT02639637 · Phase 4 · registry result, not featured evidence · combination 0% NCT02256189 · Phase 4 · registry result, not featured evidence 0% NCT01859793 · Phase 4 · registry result, not featured evidence 0% NCT02312063 · Phase 4 · registry result, not featured evidence —Metformin and Sitagliptin NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination —Metformin and Sitagliptin + Glargi NCT01845831 · Phase 4 · registry result, not featured evidence · combination 7.2%Sitagliptin + Glargine (Hospital) NCT01845831 · Phase 4 · registry result, not featured evidence · combination 0%50 mg NCT02318693 · Phase 4 · registry result, not featured evidence 3.4% NCT01907854 · Phase 4 · registry result, not featured evidence 2% NCT01686932 · Phase 4 · registry result, not featured evidence 3.6%BID + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.6%BID + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 2.1%OD + Sita + Met NCT01519674 · Phase 4 · registry result, not featured evidence · combination 0%Metformin Plus Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin NCT00820573 · Phase 4 · registry result, not featured evidence 3.7%Sitagliptin + SSI Prn NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0%Sitagliptin and Glargine + SSI NCT01378117 · Phase 4 · registry result, not featured evidence · combination 0% NCT01131182 · Phase 4 · registry result, not featured evidence 3.1%Exenatide + Placebo NCT00870194 · Phase 4 · registry result, not featured evidence 4.7%Exenatide + Sitagliptin NCT00870194 · Phase 4 · registry result, not featured evidence · combination 0% NCT00686634 · Phase 4 · registry result, not featured evidence 2.7% NCT00729326 · Phase 4 · registry result, not featured evidence 4.2%100 mg NCT04017832 · Phase 3 · registry result, not featured evidence 10.5% NCT01485614 · Phase 3 · registry result, not featured evidence 6.5%Sitagliptin/Metformin NCT01760447 · Phase 3 · registry result, not featured evidence 6.7%Sitagliptin/Metformin XR NCT01760447 · Phase 3 · registry result, not featured evidence 2.1% NCT03115112 · Phase 3 · registry result, not featured evidence 1.3% NCT02791490 · Phase 3 · registry result, not featured evidence | —Teneli / Teneli + SUk NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results0%Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.3%Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination 6.5%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination 1.3%Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 3.2%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 4.7%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.3% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 6.6%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 8%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 6.3%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 3.8%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence 5.7%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.3%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 4.3%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 4.6%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 0%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mgj upper respiratory tract infection 13.1% dizziness 11.5% nasopharyngitis 9.2% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 30 more results100 mg/100 mg upper respiratory tract infection 15.1% dizziness 10.5% nasopharyngitis 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg upper respiratory tract infection 11.4% arthralgia 9.8% blood glucose increased 8.9% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 200 mg/200 mg upper respiratory tract infection 16.4% dizziness 12.4% influenza 8.8% NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg any infections and infestations 6.3% (placebo 3.4%) upper respiratory tract infection 6.3% (placebo 3.4%) any nervous system disorders 5.1% (placebo 3.9%) NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3 infection 2% (placebo 2%) headache 1% (placebo 1%) loss of appetite 1% (placebo 0%) NCT02556918 · Phase 4 · registry result, not featured evidence 100 mg headache 1.6% hypertension 1.6% diarrhoea 0% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 15.8% arrhythmic events 5.3% genital infection 5.3% NCT02920918 · Phase 4 · registry result, not featured evidence light-headedness 7.7% (placebo 7.7%) paresthesias 7.7% (placebo 0%) nausea 0% (placebo 7.7%) NCT02639637 · Phase 4 · registry result, not featured evidence light-headedness 0% (placebo 7.7%) nausea 0% (placebo 7.7%) paresthesias 0% (placebo 0%) NCT02639637 · Phase 4 · registry result, not featured evidence · combination rash 0% (placebo 2.8%) NCT01859793 · Phase 4 · registry result, not featured evidence hypoglycemia 0% NCT02312063 · Phase 4 · registry result, not featured evidence urinary tract infection 1.4% wound infection 0% NCT01845831 · Phase 4 · registry result, not featured evidence · combination 50 mg erythema 38.5% hypoglycaemia 7.7% periodontitis 7.7% NCT02318693 · Phase 4 · registry result, not featured evidence diarrhoea 9.3% nausea 7.8% upper respiratory tract infection 6.4% NCT01907854 · Phase 4 · registry result, not featured evidence hypoglycaemia 14% blood glucose decreased 6% NCT01686932 · Phase 4 · registry result, not featured evidence influenza 5.7% nasopharyngitis 4.7% diarrhoea 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination headache 5.7% nasopharyngitis 5.7% influenza 2.6% NCT01519674 · Phase 4 · registry result, not featured evidence · combination diarrhoea 5.3% influenza 5.3% headache 4.2% NCT01519674 · Phase 4 · registry result, not featured evidence · combination hyperglycemia 11.1% pressure ulcer/skin ulcer 11.1% hypoglycemia 3.7% NCT01378117 · Phase 4 · registry result, not featured evidence · combination hypoglycemia 6.9% pneumonia 6.9% urinary tract infection 6.9% NCT01378117 · Phase 4 · registry result, not featured evidence · combination headache 4.9% dizziness 3.9% hyperhidrosis 3.7% NCT01131182 · Phase 4 · registry result, not featured evidence nausea 15.7% vomiting 10.2% nasopharyngitis 8.7% NCT00870194 · Phase 4 · registry result, not featured evidence nausea 10.2% nasopharyngitis 7.8% headache 7% NCT00870194 · Phase 4 · registry result, not featured evidence · combination nausea 37% vomiting 20.5% headache 12.3% NCT00729326 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 7.8% diarrhoea 4.5% nausea 3.9% NCT04017832 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.8% nasopharyngitis 15.8% upper respiratory tract infection 12.6% NCT01485614 · Phase 3 · registry result, not featured evidence hypoglycaemia 16.1% upper respiratory tract infection 14.5% diarrhoea 11.3% NCT01760447 · Phase 3 · registry result, not featured evidence hypoglycaemia 20% upper respiratory tract infection 11.1% abdominal pain 8.9% NCT01760447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13% hypoglycemia 5.2% influenza 5.2% NCT03115112 · Phase 3 · registry result, not featured evidence diarrhoea 7.9% (placebo 4.8%) NCT02791490 · Phase 3 · registry result, not featured evidence | k nasopharyngitis 19.8% (placebo 27.4%) upper respiratory tract inflammation 5.2% (placebo 7.4%) alanine aminotransferase increased 4.2% (placebo 3.2%) NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 23 more resultsnasopharyngitis 33.3% (placebo 27.4%) protein urine present 16.7% (placebo 13.7%) glucose urine present 11.5% (placebo 17.9%) NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 nasopharyngitis 37.1% blood creatine phosphokinase increased 9.3% protein urine present 9.3% NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 nasopharyngitis 32.6% glucose urine present 18% protein urine present 14.6% NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 nasopharyngitis 28.6% (placebo 18.3%) hypoglycaemia 27.3% (placebo 7%) constipation 10.4% (placebo 2.8%) NCT02081599 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 11.7% (placebo 7%) nasopharyngitis 7.8% (placebo 18.3%) constipation 3.9% (placebo 2.8%) NCT02081599 · Phase 4 · registry result, not featured evidence · combination 20 mg upper respiratory tract infection 11.3% (placebo 17.9%) hyperuricaemia 8.9% (placebo 10.6%) hyperlipidaemia 6.5% (placebo 5.7%) NCT02924064 · Phase 3 · registry result, not featured evidence · combination 20 mg upper respiratory tract infection 23.6% (placebo 15.7%) hyperuricaemia 8.7% (placebo 4.7%) proteinuria 7.1% (placebo 3.9%) NCT02916706 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 15.6% (placebo 10.4%) upper respiratory tract infection 5.2% (placebo 0%) NCT02354222 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 29.2% upper respiratory tract inflammation 9.4% blood urine present 7.1% NCT01301833 · Phase 3 · registry result, not featured evidence nasopharyngitis 28% upper respiratory tract inflammation 10.7% eczema 9.3% NCT01301833 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 29.5% upper respiratory tract inflammation 10.5% blood urine present 9.5% NCT01301833 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 23.8% upper respiratory tract inflammation 13.8% bronchitis 8.8% NCT01301833 · Phase 3 · registry result, not featured evidence · combination 20 mg nasopharyngitis 6.1% (placebo 0%) blood triglycerides increased 3% (placebo 3.1%) diarrhoea 3% (placebo 0%) NCT01072331 · Phase 3 · registry result, not featured evidence 10 mg upper respiratory tract inflammation 8.8% (placebo 0%) nasopharyngitis 5.9% (placebo 0%) alanine aminotransferase increased 2.9% (placebo 0%) NCT01072331 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 12.1% (placebo 6.7%) glucose urine present 4% (placebo 6.7%) upper respiratory tract inflammation 4% (placebo 3.8%) NCT00998881 · Phase 3 · registry result, not featured evidence 40 mg nasopharyngitis 8% (placebo 6.8%) cystitis 5.7% (placebo 1.1%) gastroenteritis 3.4% (placebo 2.3%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20 mg diarrhoea 5.5% (placebo 3.4%) headache 5.5% (placebo 1.1%) hypertension 3.3% (placebo 2.3%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 10 mg cystitis 4.3% (placebo 1.1%) nasopharyngitis 4.3% (placebo 6.8%) bronchitis 3.2% (placebo 1.1%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 5 mg nasopharyngitis 6.9% (placebo 6.8%) hypertension 5.7% (placebo 2.3%) bronchitis 3.4% (placebo 1.1%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20 mg nasopharyngitis 11.4% (placebo 13.8%) glucose urine present 5.1% (placebo 7.5%) urine ketone body present 5.1% (placebo 1.3%) NCT00628212 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 19% (placebo 13.8%) blood creatine phosphokinase increased 4.8% (placebo 1.3%) blood urine present 4.8% (placebo 1.3%) NCT00628212 · Phase 2 · registry result, not featured evidence 40 mg nasopharyngitis 17.3% (placebo 13.8%) arthropod sting 3.7% (placebo 0%) glucose urine present 3.7% (placebo 7.5%) NCT00628212 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: baseline_threshold differs (none recorded versus hba1c>=6.9); comorbidity_diabetes differs (required versus none recorded).
- cAssessment timepoints differ: 104 weeks versus 52 weeks.
- dTrial phases differ: Phase 4 versus Phase 3.
- ePopulation comparability has not been reviewed for both studies.
- fTreatment context has not been resolved for both arms.
- gAssessment timepoints differ: 1.857 weeks versus 4 weeks.
- hAssessment timepoints differ: 8 weeks versus 24 weeks.
- iAssessment timepoints differ: 26 weeks versus 24 weeks.
- jPopulation comparability has not been reviewed for 33 of these studies.
- kPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sitagliptin
show 3 more results
show 3 more results
show 1 more result
show 2 more results
show 1 more result
show 2 more results
+ 68 further endpoints in the CSV export.
Teneligliptin
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sitagliptin's landscape · Teneligliptin's landscape